{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:31:27Z","timestamp":1794508287908,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T00:00:00Z","timestamp":1605139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UCB JAPAN","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AYUMI Pharmaceutical","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The positivity of anti-citrullinated protein\/peptide antibodies (ACPAs) is a clinically useful diagnostic and prognostic marker in rheumatoid arthritis (RA). However, the significance of ACPA titer and its fluctuation remain unclear. This study aimed to assess the role of ACPA titer and its fluctuation on disease activity and the prognosis of RA.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Data obtained from the Kyoto University Rheumatoid Arthritis Management Alliance (KURAMA) cohort was analyzed. Patients whose ACPA was measured at least twice between 2011 and 2019 and whose ACPA was positive at least once were included in this study. The association between the clinical variable and ACPA titer or its change was investigated.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>ACPA titer was measured in a total of 3286 patients, 1806 of whom were ACPA-positive at least once. Among them, the ACPA titer level was measured more than once in 1355 patients. Very weak correlation was observed between the ACPA titer level and disease activity. Additionally, there was no trend in the fluctuation of ACPA titer level in each patient; ACPA titer level fluctuated in some patients, but not in others. Patients with high variable levels of ACPA titer were more likely to relapse from remission. In the analysis of two consecutive ACPA measurements, the titer changes predicted the relapse from remission within a year of the second measurement.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The ACPA titer level fluctuated in some patients. Very weak correlation was observed between the ACPA titer level and disease activity. Fluctuation in ACPA titer level predicted relapse from remission in patients with RA.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13075-020-02366-x","type":"journal-article","created":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T13:03:02Z","timestamp":1605186182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Fluctuation in anti-cyclic citrullinated protein antibody level predicts relapse from remission in rheumatoid arthritis: KURAMA cohort"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,12]]},"reference":[{"issue":"10055","key":"2366_CR1","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet (London, England). 2016;388(10055):2023\u201338.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"2366_CR2","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1136\/annrheumdis-2016-210602","volume":"76","author":"B Combe","year":"2017","unstructured":"Combe B, Landewe R, Daien CI, et al. 2016 update of the EULAR recommendations for the management of early arthritis. Ann Rheum Dis. 2017;76(6):948\u201359.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2366_CR3","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5114\/ceji.2017.72807","volume":"42","author":"W Kurowska","year":"2017","unstructured":"Kurowska W, Kuca-Warnawin EH, Radzikowska A, Ma\u015bli\u0144ski W. The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis. Central-Eur J Immunol. 2017;42(4):390\u20138.","journal-title":"Central-Eur J Immunol"},{"issue":"7","key":"2366_CR4","doi-asserted-by":"publisher","first-page":"456","DOI":"10.7326\/0003-4819-152-7-201004060-00010","volume":"152","author":"PF Whiting","year":"2010","unstructured":"Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med. 2010;152(7):456\u201364 w155-66.","journal-title":"Ann Intern Med"},{"issue":"8","key":"2366_CR5","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00296-016-3506-3","volume":"36","author":"E Martin-Mola","year":"2016","unstructured":"Martin-Mola E, Balsa A, Garc\u00eda-Vicuna R, et al. Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int. 2016;36(8):1043\u201363.","journal-title":"Rheumatol Int"},{"issue":"1","key":"2366_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13075-019-1815-0","volume":"21","author":"EC de Moel","year":"2019","unstructured":"de Moel EC, Derksen V, Trouw LA, et al. In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. Arthritis Res Therapy. 2019;21(1):28.","journal-title":"Arthritis Res Therapy"},{"key":"2366_CR7","doi-asserted-by":"crossref","unstructured":"Kahaly GJ, Diana T, Olivo PD. Tsh receptor antibodies: relevance & utility. Endocrine Practice 2020;26(1):97\u2013106.","DOI":"10.4158\/EP-2019-0363"},{"issue":"8","key":"2366_CR8","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1177\/0961203316651748","volume":"25","author":"R Nakashima","year":"2016","unstructured":"Nakashima R, Hosono Y, Mimori T. Clinical significance and new detection system of autoantibodies in myositis with interstitial lung disease. Lupus. 2016;25(8):925\u201333.","journal-title":"Lupus"},{"issue":"5","key":"2366_CR9","first-page":"763","volume":"36","author":"M Di Battista","year":"2018","unstructured":"Di Battista M, Marcucci E, Elefante E, et al. One year in review 2018: systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36(5):763\u201377.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"2366_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nature reviews Disease Primers. 2019;5(1):30.","journal-title":"Nature reviews Disease Primers"},{"issue":"6","key":"2366_CR11","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1756-185X.13428","volume":"22","author":"K Murata","year":"2019","unstructured":"Murata K, Ito H, Hashimoto M, et al. Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis. 2019;22(6):1084\u201393.","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"2366_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13075-019-1956-1","volume":"21","author":"T Tomizawa","year":"2019","unstructured":"Tomizawa T, Ito H, Murata K, et al. Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis. Arthritis Res Therapy. 2019;21(1):174.","journal-title":"Arthritis Res Therapy"},{"issue":"2","key":"2366_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228852","volume":"15","author":"I Murakami","year":"2020","unstructured":"Murakami I, Murakami K, Hashimoto M, et al. Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis. PLoS One. 2020;15(2):e0228852.","journal-title":"PLoS One"},{"issue":"3","key":"2366_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2366_CR15","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569\u201381.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2366_CR16","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1007\/s00296-013-2734-z","volume":"33","author":"JY Choe","year":"2013","unstructured":"Choe JY, Bae J, Lee H, Bae SC, Kim SK. Relation of rheumatoid factor and anti-cyclic citrullinated peptide antibody with disease activity in rheumatoid arthritis: cross-sectional study. Rheumatol Int. 2013;33(9):2373\u20139.","journal-title":"Rheumatol Int"},{"issue":"10","key":"2366_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00296-008-0570-3","volume":"28","author":"M Serdaro\u011flu","year":"2008","unstructured":"Serdaro\u011flu M, Cakirbay H, De\u011fer O, Cengiz S, Kul S. The association of anti-CCP antibodies with disease activity in rheumatoid arthritis. Rheumatol Int. 2008;28(10):965\u201370.","journal-title":"Rheumatol Int"},{"issue":"9","key":"2366_CR18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1111\/1756-185X.13651","volume":"22","author":"W Xie","year":"2019","unstructured":"Xie W, Li J, Zhang X, Sun X, Zhang Z. Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018. Int J Rheum Dis. 2019;22(9):1670\u20138.","journal-title":"Int J Rheum Dis"},{"issue":"8","key":"2366_CR19","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48(8):2146\u201354.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2366_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/ard.2009.119016","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis. 2010;69(3):510\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2366_CR21","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3899\/jrheum.130905","volume":"41","author":"M Scarsi","year":"2014","unstructured":"Scarsi M, Paolini L, Ricotta D, et al. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis. J Rheumatol. 2014;41(4):666\u201372.","journal-title":"J Rheumatol"},{"issue":"1","key":"2366_CR22","first-page":"53","volume":"31","author":"G Schett","year":"2017","unstructured":"Schett G. The role of ACPAs in at-risk individuals: early targeting of the bone and joints. Best practice & research. Clin Rheumatol. 2017;31(1):53\u20138.","journal-title":"Clin Rheumatol"},{"issue":"5","key":"2366_CR23","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1136\/annrheumdis-2012-202958","volume":"73","author":"A Kleyer","year":"2014","unstructured":"Kleyer A, Finzel S, Rech J, et al. Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. 2014;73(5):854\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2366_CR24","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.34344","volume":"64","author":"MK Demoruelle","year":"2012","unstructured":"Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum. 2012;64(6):1756\u201361.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2366_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1136\/annrheumdis-2015-207871","volume":"75","author":"JL Nam","year":"2016","unstructured":"Nam JL, Hunt L, Hensor EM, Emery P. Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study. Ann Rheum Dis. 2016;75(8):1452\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"2366_CR26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1002\/art.40504","volume":"70","author":"J Falconer","year":"2018","unstructured":"Falconer J, Murphy AN, Young SP, et al. Review: synovial cell metabolism and chronic inflammation in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, N.J.). 2018;70(7):984\u201399.","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"},{"issue":"10","key":"2366_CR27","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1136\/annrheumdis-2015-208495","volume":"75","author":"A Schwenzer","year":"2016","unstructured":"Schwenzer A, Jiang X, Mikuls TR, et al. Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1876\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2366_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035296","volume":"7","author":"J Sokolove","year":"2012","unstructured":"Sokolove J, Bromberg R, Deane KD, et al. Autoantibody epitope spreading in the pre-clinical phase predicts progression to rheumatoid arthritis. PLoS One. 2012;7(5):e35296.","journal-title":"PLoS One"},{"issue":"4","key":"2366_CR29","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/art.40760","volume":"71","author":"S Kongpachith","year":"2019","unstructured":"Kongpachith S, Lingampalli N, Ju CH, et al. Affinity maturation of the anti-citrullinated protein antibody paratope drives epitope spreading and polyreactivity in rheumatoid arthritis. Arthritis Rheumatol (Hoboken, N.J.). 2019;71(4):507\u201317.","journal-title":"Arthritis Rheumatol (Hoboken, N.J.)"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-020-02366-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02366-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,12]],"date-time":"2020-11-12T13:20:04Z","timestamp":1605187204000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02366-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,12]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2366"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02366-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,12]]},"assertion":[{"value":"6 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki, with approval from the ethics committee of Kyoto University Hospital (E1308). Written informed consent was obtained from all the participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.Murat. received a speaking fee and\/or consulting fee from Eisai Co., Ltd. and Astellas Pharma Inc. H.I. has received a research grant and\/or speaker fee from Bristol-Myers Squibb, Astellas Pharma Inc., Asahi Kasei Pharma Corporation, and Kyocera Medical Co. M.H. received a research grant and\/or speaker fee from Mitsubishi Tanabe Pharma Corporation; Bristol-Myers Squibb; Eisai Co., Ltd.; and Eli Lilly and Company. K. Murak. has received speaking fees and\/or consulting fees from Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Pfizer Inc.; Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation; UCB Japan Co., Ltd.; Daiichi Sankyo Co., Ltd.; and Astellas Pharma Inc. R.W. has received speaker fees from Mitsubishi Tanabe Pharma Corporation; Pfizer Inc.; Sanofi S.A.; AbbVie GK; Asahi Kasei Pharma Corporation; Eisai Co., Ltd.; Eli Lilly and Company; Bristol-Myers Squibb; and Janssen Pharmaceutical K.K. M.T. has received research grants and\/or speaker fees from AbbVie GK; Asahi Kasei Pharma Corporation; Astellas Pharma Inc.; Bristol-Myers Squibb; Chugai Pharmaceutical Co., Ltd.; Eisai Co., Ltd.; Eli Lilly and Company; Pfizer Inc.; UCB Japan Co., Ltd.; Janssen Pharmaceutical K.K.; Mitsubishi Tanabe Pharma Corporation; Novartis Pharma K.K.; Taisho Pharma Co., Ltd.; and Takeda Pharmaceutical Company Limited. S.M. has received a research grant and\/or speaker fee from Eisai Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; and Ono Pharmaceutical Co. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}